What is your approach to patients who develop ARIA-E or ARIA-H during treatment with anti-amyloid therapies?

We follow the recommendations in the drug label that depends on the severity of each ARIA (mild/moderate/severe). Depending on the severity of ARIA, treatment may be held pending follow-up evaluation or discontinued entirely.

We follow the published guidelines and the prescription information. We take into consideration the presence and severity of symptoms and ARIA severity on brain MRI.